The Lancet The Lancet, Elsevier, 2019, 394 (10204), pp.1169-1180. ⟨10.1016/S0140-6736(19)31887-2⟩ The Lancet (London), 394, 1169-1180 Bhatt, D L, Steg, P G, Mehta, S R, Leiter, L A, Simon, T, Fox, K, Held, C, Andersson, M, Himmelmann, A, Ridderstråle, W, Chen, J, Song, Y, Diaz, R, Goto, S, James, S K, Ray, K K, Parkhomenko, A N, Kosiborod, M N, McGuire, D K, Harrington, R A & THEMIS Steering Committee and Investigators 2019, ' Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial ', Lancet, vol. 394, no. 10204, pp. 1169-1180 . https://doi.org/10.1016/S0140-6736(19)31887-2 The Lancet (London), 394, 10204, pp. 1169-1180
Glidden, David; Wong, Joseph; Grant, Robert; Liegler, T; Abdel-Mohsen, M; Bentley, LG; et al.(2014). HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/4gf557rh